Development of trigger sensitive hyaluronic acid/palm oil-based organogel for in vitro release of HIV/AIDS microbicides using artificial neural networks

M O Ilomuanya,Vijayalakshimi Velusamy,A N Amenaghawon,A S Akanmu,R F Elesho,A O Adetuyi

doi:10.1186/s43094-019-0015-8

M O Ilomuanya, Vijayalakshimi Velusamy + Show 4 more

Open Access

https://doi.org/10.1186/s43094-019-0015-8

Copy DOI

Abstract

BackgroundEfficient and effective chemotherapeutic methods designed to prevent the continuous spread of HIV/AIDS is essential to break the cycle of new infections. The use of condoms has been seen to be effective in prevention of HIV and STIs but its lack of use especially in vulnerable population is a deterrent to its overall success as a control method. Utilization of topical microbicide to curb the spread of HIV follows the current paradigm for HIV prevention in at risk individuals. The objective of this study was to develop and evaluate hyaluronic acid/palm oil-based organogel loaded with maraviroc (MRV) which would be released using hyaluronidase as the trigger for pre-exposure prophylaxis of HIV.ResultsThe organogels had average globules size 581.8 ± 3.9 nm, and were stable after three freeze thaw cycles; the thermosensitive and HA sensitivity was achieved via incorporation of hyaluronic acid and dicaprylate esters in the organogel with thermogelation occurring at 34.1 °C. Artificial neural network was used to model and optimize mucin absorption and flux. These responses were predicted using the multilayer full feed forward (MFFF) and the multilayer normal feed forward (MNFF) neural networks. Optimized organogel showed the mucin adsorption and flux was 70.84% and 4.962 μg/cm2/min1/2, hence MRV was adequately released via triggers of temperature and HA. The MRV organogel showed inhibition HIV − 1 via TZM-bl indicator cells. Compared to control HeLa cells without any treatment, MRV organogel was not cytotoxic for 14 days in vitro.ConclusionThese data highlight the potential use of hyaluronic acid/palm oil-based organogel for vaginal delivery of anti-HIV microbicides. This can serve as a template for more studies on such formulations in the area of HIV prevention.

Highlights

Efficient and effective chemotherapeutic methods designed to prevent the continuous spread of HIV/ AIDS is essential to break the cycle of new infections
The optimized hyaluronic acid/palm oil (HAP) organogel was viscous with pH 4.5 and osmolality 399.1 mOsm/kg and pH 5.9 and osmolality 450.4 mOsm/ kg for the un-optimized formulation
The in vitro release study for the organogels showed a release rate of 3.894 μg/cm2/min1/2 for the HAP organogel, a higher value of 4.49 μg/cm2/min1/2 was obtained for the optimized formulation

Summary

Introduction

Efficient and effective chemotherapeutic methods designed to prevent the continuous spread of HIV/ AIDS is essential to break the cycle of new infections. Utilization of more potent antiviral agents in novel formulation that target the virus at critical steps in its replication cycles are pertinent in the discovery of the ideal HIV microbicide [1]. These potent antiviral agents require a drug carrier that meets the requirements for vaginal delivery which include cervicovaginal tissue safety and ease of application by clients [2, 3]. Ilomuanya et al Future Journal of Pharmaceutical Sciences gp120 subunit of the viral envelope glycoprotein, causing gp 120 conformational change disruption This prevents CCR5-tropic HIV-1 fusion with the CD4 cell inhibiting cell entry [6]. Hyaluronic acid (HA) is hydrolysable under treatment with the hyaluronidase enzyme, which is abundant in human seminal fluid [10] as well as other body fluids and tissues [10, 11]

Objectives

Methods

Results

Discussion

Conclusion